We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
News

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
News

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affectis Granted Patent for AFC-5128, other P2X7 Antagonists"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The European patent EP2105164 is related to the composition of AFC-5128, a highly potent orally active P2X7 antagonist. A key advantage of the compound is its ability to cross the blood-brain barrier and target P2X7-expressing CNS-cells such as glia and oligodendrocyte cells which are linked to neurodegenerative processes. Affectis has shown that oral administration of AFC-5128 significantly reduces clinical scores and frequency of relapse in a mouse model of multiple sclerosis.

Strong analgesic effects have also been observed in animal models of inflammatory and neuropathic pain. With these efficacy data available, Affectis is on track for filing an IND in 2012 for neuropathic pain and multiple sclerosis.

The granted patent also covers the composition of further P2X7 antagonist compounds. Affectis has filed corresponding patent applications that are being processed in major markets such as the USA, Japan, China, among others.

Dr. Manfred Ruediger, CEO of Affectis, commented, "The issuance of this patent, the confirmation of the efficacy of AFC-5128 in various animal models and the license agreement entered with Merck Serono on a separate program are all important achievements that occurred in the past year."

Advertisement